Hemoglobin E (HbE) is caused by a G→A mutation at codon 26 of the β-globin gene, which substitutes Glu→Lys. This mutation gives rise to functional but unstable hemoglobin and activates a cryptic splice site causing mild anemia. HbE reaches a carrier frequency of 60-80% in some Southeast Asian populations. HbE causes serious disease when co-inherited with a β-thalassemia mutation. In this study, we report the creation and evaluation of humanized transgenic mice containing the β E mutation in the context of the human β-globin locus. Developmental expression of the human β E locus transgene partially complements the hematological abnormalities in heterozygous knockout mice ( mu β th-3/+ ) and rescues the embryonic lethality of homozygous knockout mice ( mu β th-3/th-3 ). The phenotype of rescued mice was dependent on the transgene copy number. This mouse model displays hematological abnormalities similar to HbE/β-thalassemia patients and represent an ideal in vivo model system for pathophysiological studies and evaluation of novel therapies.
Hemoglobin E (HbE) is the common hemoglobin variant, most prevalent in the rapidly expanding populations of Southeast Asia, but it is also encountered with increasing frequency in Europe, North America, and Australia due to increasing immigration from Southeast Asia [1] . Although HbE was first identified in 1954 [2] there are still uncertainties about aspects of the pathophysiology of the associated hemoglobinopathy. Both heterozygotes and homozygotes are mildly anemic, with microcytic and hypochromic erythrocytes. This is consistent with the thalassemic nature of the β E mutation, in which a cryptic donor splice site is activated by the G→A mutation in exon 1 of the β-globin gene [3] . However, when the β E allele interacts with a β-thalassemia mutation in the compound heterozygous state, an often severe but variable anemia is produced, with hemoglobin levels from 3 to 11 g/dl [4] .
Five β-thalassemia mouse models have been described. These models comprise a naturally occurring deletion (Hbb th-1 ) [5] , an insertional disruption (Hbb th-2 ) [6] , or a complete deletion of the mouse β-globin genes (Hbb 0 and Hbb th-3 ) [7, 8] . A range of disease severity including mild anemia, thalassemia intermedia, or embryonic lethality was observed in these models. These mice mimic the β-thalassemia phenotype seen in humans and can be used to study approaches to gene therapy based on gene supplementation [9, 10] . However, none of these models reproduces β-thalassemia as seen in humans at the genotypic level, thus limiting the development of therapeutic strategies that are not based on gene supplementation. An additional knock-in model carrying a single copy of the human β-globin gene with the IVSII-654 C→T splicing mutation in place of the mouse β-globin genes (Hbb th-4 ) was developed [11] . This model is valuable for the in vivo development of antisense oligonucleotides therapy to restore splicing specificity.
Transgenic mice expressing HbE have been recently generated using a 12-kb DNA fragment containing human β E -and human α-globin genes linked to the human β-globin locus control region [12] . Mice expressing the human β E gene on a full mouse α-globin knockout and a partial mouse β-globin knockout background have red cell abnormalities similar to those of HbE and HbE/β 0 -thalassemia patients. However, the lack of the γ-globin genes and the absence of other cis-acting regulatory elements that control the expression of the β-globin locus in the transgene fragment used to generate this model have limited its use for pharmacological up-regulation of γ-globin gene expression, a potential therapy for HbE/β-thalassemia [13, 14] .
We have used a 183-kb genomic fragment containing the human β-globin locus to generate transgenic mice [15] . Developmentally appropriate expression of the globin genes from the human β-globin locus transgene was able to rescue the embryonic lethal homozygous β-globin knockout embryos ( mu β th-3/th-3 ) [15] . Using the GET Recombination system [16] , we introduced several common β-thalassemia mutations [17] [18] [19] , including β E and a deletion of codons 41-42 (-TTCT) in the β-globin gene [20] , within the human β-globin locus contained in a 183-kb genomic fragment. We have recently reported the first humanized mouse model for the deletion of codons 41-42 [21] . Unlike the situation with the normal human β-globin locus [15] , these mutant mice fail to show any phenotypic complementation in heterozygous or homozygous knockout mice. This is a valuable model for gene correction in hemopoietic stem cells and for studying the effects of HbF inducers in vivo in a humanized thalassemic environment.
In this study, we report the creation and evaluation of humanized transgenic mice containing the β E mutation in the context of the human β-globin locus. We show that these mouse models display hematological abnormalities at phenotypic and genotypic levels similar to HbE homozygotes and HbE/β-thalassemia patients. These mice represent an ideal in vivo model system for pathophysiological studies and evaluation of novel therapies.
Results
Transgenic founder mice contain a single transgene integration site and two to four copies of the human β E transgene
We generated five transgenic founder mice, of which three transmitted the transgene to progeny. Using fluorescence in situ hybridization (FISH) analysis, we showed that transgenic line 1 (Fig. 1A) and the other two transmitting lines contained a single integration site of the transgene (data not shown). Transgenic line 1 contained four copies of the transgene, and lines 2 and 3 contained two copies, as determined by Southern blot hybridization (Fig. 1B) . The overall integrity of the transgene fragment evaluated by multiplex PCR using primer pairs for 5′ HS-5, 5′HS-2, human ϵ-globin, human γ-globin, and human δ-globin genes as previously described [21] showed that all founders produced all the expected fragments (data not shown).
The overall functionality of the human β E -globin locus transgene in these mice was evaluated by complementation of the embryonic lethality of homozygous knockout mu β th-3/th-3
embryos. We bred all transmitting lines with the heterozygous β-globin knockout mice ( mu β th-3/+ ) [8] to produce mice hemizygous for the transgene on a heterozygous knockout background ( hu β E/0 , mu β th-3/+ ), referred to as "double heterozygous" (DH). DH mice were then bred together to generate mice hemizygous ( hu β E/0 , mu β th-3/th-3 ) or homozygous for the transgene ( hu β E/E , mu β th-3/th-3 ) on a homozygous knockout background, referred to as "rescued mice".
Human β E transgene expression in adult transgenic mice is copy number dependent
To determine the relative expression of the human β Eglobin and the endogenous mouse β-globin genes (β maj and β min ), we performed a semiquantitative RT-PCR analysis using primers flanking exons 1 and 2 of the β-globin gene. These primers amplify equally well on the mouse and human β-globin mRNAs and produce a 252-bp product from both mouse and human β-globin. The human β-globin cDNA could be distinguished from the mouse β-globin cDNA by digestion with NcoI, which cuts only the mouse β-globin cDNA PCR product into two 126-bp fragments ( Fig. 2A) . We demonstrated that the human β E -globin mRNA was detected in the peripheral blood of mice carrying the hemizygous transgene on a wild-type background in all three mouse lines (Fig. 2B ). An increase in the expression of the human β Eglobin relative to the mouse β-globin was observed in DH mice for all three lines (Fig. 2B) . The finding that line 1, containing four copies of the transgene, has a higher level of human β-globin mRNA than the other two lines (two copies of the transgene) indicates that transgene expression increases with an increase in transgene copy number. We obtained similar results with transgenic mice carrying the normal human β-globin locus [15] .
Aberrant splicing of the β E -globin pre-mRNA in the β
E transgenic mice
To determine whether the β E -globin pre-mRNA in transgenic mice is aberrantly spliced as it is in humans, we performed RT-PCR analysis on RNA derived from bone marrow. Aberrant splicing of the β E -globin pre-mRNA should result in a PCR product that is truncated by deletion of 16 nucleotides from the 3′ end of exon 1 (Fig. 2C ). All three DH mouse lines showed the presence of a 303-bp product of correctly spliced β E -globin mRNA and a 287-bp product (deletion of 16 bp) of aberrantly spliced β E -globin mRNA (Fig.  2D ). This result confirmed that the β E G→A mutation from the transgene locus in transgenic mice produces the same aberrant spliced product found in patients carrying the β E mutation. Thus this model is valuable for the in vivo development of antisense oligonucleotides to restore splicing specificity, a potential therapeutic approach to splicing defects in HbE/β-thalassemia patients [22, 23] .
Human β E transgene expression complements hematological abnormalities in the mu β th-3/+ mice
The hematologic indices of the β E , mu β th-3/+ , and wild-type mice at 6-8 weeks of age are summarized in Table 1 . The mu β th-3/+ mice are more anemic compared to human β-thalassemia heterozygotes (β-thalassemia traits), as is reflected in the markedly decreased hemoglobin concentration, hematocrit and red blood cell (RBC) count, as well as by the increased red cell distribution width (RDW) and reticulocyte count. The red cells from such mice also show marked hypochromia, anisocytosis, poikilocytosis, and target cells in comparison to normal mouse red cells (Table 1, Figs. 3A and 3B) . However, the reduction in mean cell volume and mean cell hemoglobin is less than in human β-thalassemia heterozygotes. Furthermore, there is no indication of any compensatory erythropoiesis in the mu β th-3/+ mice as reflected by a dramatic reduction in red cell counts, unlike in human β-thalassemia heterozygotes, in which there is a compensatory erythropoiesis resulting in an elevated RBC count [24] . This appears to be due to the highly efficient removal of immature red cell precursors expressing an excess of α-globin chains [25] . The presence of the human β E -globin locus transgene on a wild-type mouse background did not have any noticeable effect on mouse hematology (data not shown). However, the presence of the human β E -globin locus transgene on a heterozygous knockout background ( hu β E/0 , mu β th-3/+ ) partially complemented the hematological abnormalities that are found in the mu β th-3/+ mice ( Table 1 , Fig. 3C ), although there was some variability in the degree of complementation among the three human β E mouse lines (Table 1) . Spleen and liver weights of the β E , mu β th-3/+ , and wildtype mice were determined. The mu β th-3/+ mice showed a highly significant increase in spleen weight compared to wildtype mice (Table 1) . In all three β E DH mouse lines, expression from the human β E locus allowed complementation of the spleen pathology ( Table 1 ). The degree of complementation in spleen pathology correlated well with the normalization of hematologic values, with the β E mouse line 3 showing the lowest hemoglobin level and having the largest spleen (Table 1) . There was no difference in the ratio for liver between wild-type, mu β th-3/+ , and all β E DH mouse lines (data not shown). The elevated serum bilirubin concentration in mu β th-3/+ indicates increased red cell turn over and hemolysis. The high reticulocyte counts and low red blood cell counts indicated that both production and destruction of erythrocytes are increased in mu β th-3/+ mice compared to wildtype mice (Table 1) . These hematological abnormalities were partially complemented by the human β E locus transgene in DH mice.
Developmental expression of the hu β E transgene locus rescues embryonic lethal mu β th-3/th-3 mice
To ascertain if the human β E locus transgene in mice is able to rescue the lethality of the mu β th-3/th-3 embryos, we further intercrossed the DH mice. Genotyping was performed by multiplex PCR using primers specific for the human β-globin gene, mouse β-globin gene, and HPRT cassette in the knockout mice as previously described [15] . With this breeding strategy, 1 in 16 pups are expected to be homozygous for the HbE locus transgene on a homozygous β-globin knockout background (homozygous rescued mice) and 2 in 16 pups are expected to be hemizygous for the transgene on a homozygous β-globin knockout background (hemizygous rescued mice). We screened 162, 81, 115, and 82 mice from breeding of line 1 × line 1, line 2 × line 2, line 3 × line 3, and line 1 × line 2, respectively, and obtained 26, 14, 19, and 17 rescued mice, respectively. The rescued progeny were obtained from all three mouse lines with the expected ratio; however, 65% of rescued progeny died within the first day after birth. Only some of the progeny (35%) survived to adulthood. Since the viability of the rescued pups after birth could depend on the level of the human β E expression, transgene copy number was determined by FISH. All of the adult rescued mice from line 1 × line 1 (Fig. 4A) , line 1 × line 2, and line 2 × line 2 (data not shown) were homozygous for the transgene (i.e., eight, six, and four copies, respectively). The finding that no adult rescued mice hemizygous for the transgene were obtained indicates that the dosage of the β E transgene on the homozygous knockout background has a direct effect on the severity of the rescued mice. These findings confirm our studies with the normal human β-globin locus, of which at least four copies are necessary to rescue the embryonic lethal mu β th-3/th-3 embryos [15] . Red blood cell abnormalities were also restored by the β E transgene in rescued mice from breeding of line 1 × line 1 (eight copies of transgene), although the RDW remained somewhat elevated (Table 1) , with some target cells and hypochromia still detectable (Fig. 3D) . Interestingly, crossbreeding of mice from line 1 × line 2 resulted in adult rescued mice with an intermediate hematological picture indicating incomplete complementation in mice with an intermediate transgene copy number (six copies of the transgene) (Fig. 3E) . A more severe phenotype was observed in rescued mice containing the lowest transgene copy number (four copies of the transgene from line 2 × line 2) (Fig. 3F) .
The presence of the heterotetramer hemoglobin ( mu α 2 / hu β E 2 ) and individual globin chain in the β E mice was demonstrated using cellulose acetate and Triton X acid urea gel electrophoresis (Figs. 4B and 4C ). The β E DH mouse contained a slower migrating hemoglobin heterotetramer comprising mouse α-globin and human β E -globin chains ( mu α 2 / hu β E 2 ) (Fig. 4B) . Analysis of adult rescued mouse blood samples showed the presence of only the mu α 2 / hu β E 2 hemoglobin (Fig. 4B) . The heterotetrameric hemoglobin was also analyzed by HPLC. Although the human β E -globin chain was found to elute at the same position as the mouse β-globin chain, analysis of the β-globin fraction by tandem mass spectroscopy yielded a mass ratio of 15,870.5 daltons, which is consistent with the expected mass ratio of the human β E -globin chain. Last, Triton X acid urea gel of a blood sample from an adult β E rescued mouse showed the presence of only the human β E -globin chain and the total absence of mouse β-globin chains (Fig. 4C) .
Discussion
A large number of mutations have been described in the human β-globin locus causing thalassemia or various hemoglobinopathies [26] . However, only the HbS variant has been modeled up to now in the context of the intact human β-globin locus in transgenic mice [27] . The β E mutation results in both a variant hemoglobin and a splicing defect, since the mutation is present in an exon and also activates a cryptic splice site. The normal splicing of the mutant gene results in a variant β-globin chain, while aberrant splicing deletes 16 bp of exon 1 from the mature mRNA. Restoration of correct splicing of β E mRNA by antisense oligonucleotides [22, 23] may thus be a possible way to ameliorate the severity of HbE/β-thalassemia patients.
Alternatively, targeted up-regulation of the γ-globin genes expression may be beneficial for β E as well as other types of β-globin mutations [13, 14] .
Large genomic inserts in BACs are more likely to contain the whole set of regulatory elements required for tissue-specific and position-independent transgene expression [28] . The development of methods for engineering BACs and the use of BACs in transgenesis have allowed the discovery of new genes by complementation of mutations, the identification of key regulatory sequences within genomic loci that are crucial for the proper expression of genes, and the design of improved animal models of human genetic diseases [29] . To produce a mouse model of HbE/β-thalassemia that recapitulates not only the phenotypic symptoms but also the correct underlying molecular defects as found in patients, we generated a transgenic/knockout mouse model for the β E mutation in the context of the intact genomic human β-globin locus from a 205-kb β-globin BAC clone. These mice exhibit hematological and pathophysiological symptoms mirroring those of human HbE and HbE/β-thalassemia diseases. A low dosage of the human β E locus transgene on a mu β th-3/th-3 background is associated with severe anemia and neonatal death, while an increased dosage of the human β E transgene allows some mice to develop to adulthood with hematological abnormalities similar to those of HbE/β-thalassemia patients.
In conclusion, the β E mouse model generated in this study complements existing models that allow preclinical testing of gene therapy approaches. They will be of particular value in allowing evaluation of therapeutic approaches that depend on the pharmacological reversal of the splicing defect in the mRNA coding for β E -globin, or the reactivation of fetal globin gene expression, as well as pathophysiological studies of iron overload, oxidative stress, and red cell membrane abnormalities.
Materials and methods
Insertion of the β E mutation into a human β-globin BAC clone Two-step GET Recombination in combination with the EcoRI/Kan R counterselection cassette was used to introduce the β E mutation into pEBAC148/β, a 205-kb BAC carrying the entire human β-globin locus. In the first stage of GET Recombination, the EcoRI/Kan R cassette was inserted into intron 1 of the human β-globin gene. This was subsequently knocked out in a second round of GET Recombination by a PCR fragment from genomic DNA of a homozygous β E subject [20] .
Preparation of a 183-kb β E -globin locus for microinjection BAC DNA was purified by cesium chloride gradient ultracentrifugation. The 183-kb genomic insert containing the human β E -globin locus was released from the vector backbone by digestion of 50 μg of purified BAC DNA with NotI and separated by pulsed-field gel electrophoresis as previously described [15, 21] . The DNA fragment was microinjected into C57BL/6 fertilized oocytes to generate transgenic mice.
Transgene analysis
FISH analysis using the pEBAC148/β probe on fibroblasts grown from mouse tail samples was used to determine the number of integration sites as previously described [15, 21] . The transgene copy number was determined by Southern blot analysis using the human β-globin probe amplified by the LUG1A/LUG2A primers [15, 21] . Genomic DNA from transgenic mice was extracted from tail biopsies, and control human genomic DNA was extracted from peripheral blood by phenol/chloroform extraction. The DNA concentration was measured by spectrophotometry. A total of 10 μg of genomic DNA of each sample was digested with EcoRI and HpaI overnight. The high degree of homology exhibited by all the members of the human β-globin gene family with respect to the region amplified by the LUG1A/LUG2A primers allows simultaneous detection of 2.2-kb human β-globin and 2.0-kb human δ-globin fragments. The transgene copy number was estimated by comparing the relative intensity of the human β-globin fragment from human genomic DNA (two copies/cell) to the intensity of the human β-globin fragment present in transgenic mice using Gene tools (Syngene, UK).
Quantitation of human and mouse β-globin mRNA
Isolation of total RNA from peripheral blood and bone marrow samples was performed using the TRI-BD reagent (Molecular Research Center, Inc.). RNA was converted into cDNA using SuperScript II reverse transcriptase (Gibco BRL). cDNA template was used as template for PCR using primers Exon1-F (5′-GATGAAGTTGGTGGTGAGGCCCT-3′) and Exon2-R (5′-CCTGAAGTTCTCAGGATCCAC-3′). These primers anneal to identical sequences on the mouse and human β-globin cDNAs to yield a 252-bp product. The human β-globin mRNA product could be distinguished from the mouse β-globin mRNA product by digestion with NcoI, which cuts the mouse β-globin PCR product (but not the human β-globin PCR product) into two 126-bp fragments.
Determination of aberrant splicing induced by the β E mutation
The primers used to determine aberrant splicing of the human β-globin premRNA were Exon1 βE-F (5′-AGGTGAACGTGGATGAAGTTG-3′) and Exon3-R (5′-AGTGATGGGCCAGCACACAG-3′). These primers amplify a 303-bp product from correctly spliced β E mRNA and a 287-bp product (deletion of 16 bp) from aberrantly spliced β E mRNA.
Hematologic analysis
EDTA blood was used for hematological analysis. Blood smears were stained with Wright's stain (Sigma). Hematologic profiles were obtained with an automatic blood counter (Roche Cobas Helios hematology analyzer). Hemoglobin analysis was performed as previously described [30] . Samples containing approximately equal amounts of hemoglobin were run on cellulose acetate membranes (Helena Laboratories). Hemoglobin bands were visualized by Ponceau S staining. Globin chain separation was performed by Triton X acid urea gel electrophoresis as previously described [31] .
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